A group of 29 nonprofit organizations filed a letter with the FDA calling on them to foster the development of a robust biosimilars market, which would ultimately reduce prescription drug costs and provide patients with access to more affordable therapies. The letter is available online.
Earlier this year, the House removed a bipartisan generic drug measure from an act approving the federal budget. The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act is pro-consumer legislation. CREATES gives generic drug makers sufficient paid access to enough samples of the patent drug that they need to complete formal FDA equivalency […]
Today, forty-five organizations sent a letter to the US Senate calling for an end to the anticompetitive abuses that block competitive market entry by generic drug makers, which work to keep drug prices higher. A copy of the letter is available here.